Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

4

Indication details

Combined Agent(s)
ADT ((androgen deprivation therapy) + docetaxel
Control Arm
ADT + Docetaxel + placebo
Therapeutic Indication
For adult patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Tumour Type
Genitourinary Cancers
Tumour Sub-type
Prostate cancer
Tumour Stage
Metastatic
Trial Name
ARASENS
NCT Number
NCT02799602
Trial Phase
Phase III

Approval details

FDA Approval
FDA approval August 2022
EMA Approval
EMA (CHMP) January 2023 EC decision March 2023

Primary Outcome(s)

Primary Outcome(s)
OS
Evaluated Outcome
OS
Form(s)
Form 2a

Outcome Data

OS Control
48.9 months*
OS Gain
23.0 months (Calculated estimate of gain based on PE HR 0.68)
OS HR
0.68 (0.57-0.80)

Adjustments

QoL Comment
QoL was not a prespecified endpoint

Score (after adjustments)

Preliminary non-curative score

4

Non-curative score

4

Comment
*OS of the control arm may be overestimated by inadequate post-progression treatment of control arm patients with abiraterone or enzalutamide when castrate resistant

Scorecard details

ESMO-MCBS version
ESMO-MCBS v1.1
Scorecard ID
352
Scorecard version
1
Issue date
22.09.2022
Last update
10.02.2023
Darolutamide ARASENS

PRELIMINARY SCORE

OS

ADJUSTMENTS

Darolutamide ARASENS

SCORE

Overall Survival / Disease-Free Survival / Pathological Complete Response
4
Overall Survival
Progression-Free Survival
Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate
Overall Response Rate / Duration of Response
Genitourinary Cancers
For adult patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Darolutamide + ADT ((androgen deprivation therapy) + docetaxel
ADT + Docetaxel + placebo

My watchlist

    pdf
    pptx

    Legend

    Information about symbols, abbrevations and color codes

    Red = negative
    Green = positive
    Grey = neutral
    ? Grey + ? = neutral with pending data
    DFS
    Disease-Free Survival
    DoR
    Duration of Response
    EFS
    Event-Free Survival
    HR
    Hazard Ratio
    NEB
    No evaluable benefit
    NI
    Non-inferiority Study
    ORR
    Overall Response Rate
    OS
    Overall Surival
    pCR
    Pathological Complete Response/Remission
    PFS
    Progression-Free Survival
    QoL
    Quality of Life
    RFS
    Relapse-Free Survival
    RR
    Response Rate

    QoL adjustments

    Other adjustments*

    Serious and disabling adverse effects

    Red = negative / deterioration

    Green = positive / improvement

    QoL adjustments

    Red = negative / deterioration

    Green = positive / improvement

    Other adjustments*

    Red = negative / deterioration

    Green = positive / improvement

    Serious and disabling adverse effects

    Red = negative / deterioration

    Green = positive / improvement

    * Other adjustments include:

    - Long-term plateau in the survival curve
    - Long-term plateau in the PFS curve
    - Early stopping or crossover
    - Only improved PFS mature data shows no OS advantage and no improved Qol.

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings
    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.